This company has been marked as potentially delisted and may not be actively trading. NASDAQ:BXRX Baudax Bio (BXRX) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Baudax Bio Stock (NASDAQ:BXRX) Get Baudax Bio alerts:Sign Up Key Stats Today's Range$0.02▼$0.0250-Day Range$0.02▼$0.0352-Week Range$0.01▼$3.47Volume310,872 shsAverage Volume281,029 shsMarket Capitalization$1.14 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care related settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with other non-NSAID analgesics. It also develops BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMB, which is in phase I clinical trial, as well as a proprietary blockade reversal agent; and BX3000, a NMB reversal agent that is in preclinical studies. Baudax Bio, Inc. was incorporated in 2019 and is based in Malvern, Pennsylvania. Read More Receive BXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Baudax Bio and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BXRX Stock News HeadlinesBaudax Bio Announces Corporate UpdateOctober 18, 2023 | finance.yahoo.comBaudax's (BXRX) Hemophilia A Drug Gets FDA's Orphan Drug TagOctober 2, 2023 | msn.comForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be the biggest paradigm shift ever. Yes, even bigger than AI. And he found one Seattle company that's at the center of this new $100 trillion revolution. Click here to get the name of this company, completely free of charge...October 11 at 2:00 AM | Brownstone Research (Ad)Why Is Baudax Bio (BXRX) Stock Up 75% Today?September 28, 2023 | investorplace.comBaudax Bio Shares Double After Orphan Drug Designation for TI-168September 28, 2023 | marketwatch.comBaudax Bio: FDA Grants Orphan Drug Designation To TI-168 For Hemophilia A With InhibitorsSeptember 28, 2023 | markets.businessinsider.comHere's Why Baudax Bio, Inc. (BXRX) Is a Great 'Buy the Bottom' Stock NowSeptember 18, 2023 | finance.yahoo.comBaudax Bio to Participate in the H.C. Wainwright Global Investment ConferenceSeptember 7, 2023 | finance.yahoo.comSee More Headlines BXRX Stock Analysis - Frequently Asked Questions How were Baudax Bio's earnings last quarter? Baudax Bio, Inc. (NASDAQ:BXRX) released its quarterly earnings data on Wednesday, August, 16th. The company reported ($1.49) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.04) by $0.55. When did Baudax Bio's stock split? Baudax Bio shares reverse split on the morning of Wednesday, November 30th 2022.The 1-40 reverse split was announced on Wednesday, November 30th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 30th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Baudax Bio own? Based on aggregate information from My MarketBeat watchlists, some other companies that Baudax Bio investors own include Vanguard Dividend Appreciation ETF (VIG), Vanguard Total Stock Market ETF (VTI), iShares Russell 1000 Growth ETF (IWF), Schlumberger (SLB), ARK Innovation ETF (ARKK), Meta Platforms (META) and NVIDIA (NVDA). Company Calendar Last Earnings8/16/2023Today10/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BXRX CIK1780097 Webwww.baudaxbio.com Phone484-395-2440Fax484-395-2471Employees9Year Founded2019Profitability EPS (Trailing Twelve Months)($9.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$58.79 million Net MarginsN/A Pretax Margin-18,950.64% Return on EquityN/A Return on Assets-175.11% Debt Debt-to-Equity RatioN/A Current Ratio0.07 Quick Ratio0.07 Sales & Book Value Annual Sales$1.27 million Price / Sales0.90 Cash FlowN/A Price / Cash FlowN/A Book Value($14.93) per share Price / Book0.00Miscellaneous Outstanding Shares52,460,000Free Float52,408,000Market Cap$1.14 million OptionableNot Optionable Beta1.57 Social Links Reduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free Report This page (NASDAQ:BXRX) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Baudax Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Baudax Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
